Neurotrophic Keratopathy clinical trials at UCSD
1 in progress, 0 open to eligible people
Showing trials for
0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2
Sorry, not currently recruiting here
The objective of this study is to compare the safety and efficacy of RGN-259 to placebo for the treatment of Neurotrophic Keratopathy (NK)
San Diego, California and other locations
Our lead scientists for Neurotrophic Keratopathy research studies include Weldon Haw, M.D..
Last updated: